Regeneron (REGN) Announces FDA Approval of Kevzara
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures subdued as investors weigh earnings, oil prices
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil prices hit fresh 6-week highs on renewed Middle East tensions
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica
February 28, 2023 8:00 PM ESTThree times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial
Kevzara now approved to treat two chronic inflammatory disorders
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Kevzara® (sarilumab) for the treatment of polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.
... More